All News SAMSUNG PHARM. Co., LTD.

Equities

A001360

KR7001360007

End-of-day quote Korea S.E. Other stock markets 23:00:00 27/05/2024 BST			5-day change	1st Jan Change
1,643 ^KRW	+0.43%		-1.20%	-24.46%

2023	NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.	CI
2023	NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.	CI

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.	06/08/23	CI
NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.	12/06/23	CI
Gemvaxzio Co., Ltd. announced that it has received KRW 7.3 billion in funding from SAMSUNG PHARM. Co., LTD.	08/12/21	CI
SAMSUNG PHARM. Co., LTD. Present Pancreatic Cancer Immunotherapeutic Drug, RIAVAX™, Phase III results at ASCO 2021	05/06/21	CI
An unknown buyer agreed to acquire 38.7% stake in Korea Stem Cell Bank Co., Ltd. from SAMSUNG PHARM. Co., LTD. for KRW 9.9 billion.	29/12/20	CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 9.999996279 billion in funding	01/03/20	CI
SAMSUNG PHARM. Co., LTD. announced that it expects to receive KRW 9.999996279 billion in funding	20/02/20	CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 21.7 billion in funding from Kiwoom Investment Co., Ltd., Sangsangin Plus Savings Bank Co.,Ltd.	13/02/20	CI
SAMSUNG PHARM. Co., LTD. completed the acquisition of an unknown minority stake in True Life Insurance Bank for KRW 12.5 billion.	22/04/19	CI
SAMSUNG PHARM. Co., LTD. acquired 3.1% stake in Enerzent Co., Ltd. for KRW 3 billion.	17/01/19	CI
SAMSUNG PHARM. Co., LTD. acquired 0.16% stake in GemVax Technology Co., Ltd. from Samsung Medicos Co., Ltd. for approximately KRW 220 million.	05/11/17	CI
Korea Stem Cell Bank Co., Ltd. agreed to acquire Samsung Medicos Co., Ltd. from SAMSUNG PHARM. Co., LTD. for KRW 16.3 billion.	30/10/17	CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 1.5 billion in funding from J & J Investment Co Ltd and other investor	18/05/17	CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 10.2 billion in funding from a group of investors	05/02/17	CI
Samsung Pharmaceutical Co., Ltd. announced that it has received KRW 5.65 billion in funding	23/10/16	CI
Samsung Pharmaceutical Corporation(KOSE:A001360) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	01/12/15	CI
Samsung Pharmaceutical Co., Ltd. announced that it has received KRW 14.5 billion in funding from a group of investors.	22/10/15	CI
Samsung Pharmaceutical Co., Ltd. announced that it expects to receive KRW 14.5 billion in funding from a group of investors.	18/10/15	CI
Samsung Pharmaceutical Co., Ltd. completed the sale of 17.13% stake in Medizen Humancare Co.,Ltd.	04/10/15	CI
Samsung Pharmaceutical Corporation(KOSE:A001360) added to S&P Global BMI Index	21/09/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News SAMSUNG PHARM. Co., LTD.

Equities

A001360

KR7001360007

All News

Filters